Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53

Background:Primary radiotherapy (RT) is a mainstay of treatment for laryngeal squamous cell carcinoma (LSCC). Although the cure rates for early (T1) vocal cord tumours are high, RT proves ineffective in up to a third of T3 carcinomas. Moreover, RT is associated with debilitating early- and late-treatment-related toxicity, thus finding means to de-escalate therapy, while retaining/augmenting therapeutic effectiveness, is highly desirable. p53 is a key mediator of radiation responses; we therefore investigated whether Nutlin-3, a small-molecule inhibitor of MDM2 (mouse double minute 2; an essential negative regulator of p53), might radiosensitise LSCC cells.Methods:We performed clonogenic assays to measure radiosensitivity in a panel of LSCC cell lines (for which we determined p53 mutational status) in the presence and absence of Nutlin-3.Results:LSCC cells harbouring wild-type p53 were significantly radiosensitised by Nutlin-3 (P<0.0001; log-rank scale), and displayed increased cell cycle arrest and significantly increased senescence (P<0.001) in the absence of increased apoptosis; thus, our data suggest that senescence may mediate this increased radiosensitivity.Conclusion:This is the first study showing Nutlin-3 as an effective radiosensitiser in LSCC cells that retain wild-type p53. The clinical application of Nutlin-3 might improve local recurrence rates or allow treatment de-escalation in these patients.

[1]  J. Califano,et al.  The molecular biology of laryngeal cancer. , 2002, Otolaryngologic clinics of North America.

[2]  H. Hermeking,et al.  14-3-3 proteins in cell cycle regulation. , 2006, Seminars in cancer biology.

[3]  D. Schwartz,et al.  Antibodies to human squamous cell carcinoma , 1983, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[4]  K. Kinzler,et al.  p21 is necessary for the p53-mediated G1 arrest in human cancer cells. , 1995, Cancer research.

[5]  D. Terrian,et al.  A Dominant Role for p53-Dependent Cellular Senescence in Radiosensitization of Human Prostate Cancer Cells , 2007, Cell cycle.

[6]  J. Califano,et al.  Human Papillomavirus and Head and Neck Squamous Cell Carcinoma: Recent Evidence and Clinical Implications , 2009, Journal of dental research.

[7]  C. Harris,et al.  The IARC TP53 database: New online mutation analysis and recommendations to users , 2002, Human mutation.

[8]  C Roskelley,et al.  A biomarker that identifies senescent human cells in culture and in aging skin in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[9]  A. Levine,et al.  The p53-mdm-2 autoregulatory feedback loop. , 1993, Genes & development.

[10]  F. Berrino,et al.  Variation in survival of patients with head and neck cancer in Europe by the site of origin of the tumours. EUROCARE Working Group. , 1998, European journal of cancer.

[11]  D. Lane,et al.  P53 in cancer: a paradigm for modern management of cancer. , 2005, The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland.

[12]  T. Carey,et al.  Evidence that loss of chromosome 18q is associated with tumor progression. , 1997, Cancer research.

[13]  Marina Konopleva,et al.  MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. , 2005, Blood.

[14]  S Rozen,et al.  Primer3 on the WWW for general users and for biologist programmers. , 2000, Methods in molecular biology.

[15]  A. Jochemsen,et al.  Mdmx and Mdm2: Brothers in Arms? , 2004, Cell cycle.

[16]  K. Vousden,et al.  Activation and activities of the p53 tumour suppressor protein , 2001, British Journal of Cancer.

[17]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[18]  D. Hallahan,et al.  Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2 , 2006, Molecular Cancer Therapeutics.

[19]  O. Myklebost,et al.  Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[21]  Hong Yang,et al.  Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. , 2005, Cancer research.

[22]  T. Pawlik,et al.  Role of cell cycle in mediating sensitivity to radiotherapy. , 2004, International journal of radiation oncology, biology, physics.

[23]  K. Vousden.  Outcomes of p53 activation - spoilt for choice , 2006, Journal of Cell Science.

[24]  T. Carey,et al.  Human squamous cell carcinoma. Establishment and characterization of new permanent cell lines. , 1981, Archives of otolaryngology.

[25]  U. Knippschild,et al.  Posttranslational modification of MDM2. , 2003, Molecular cancer research : MCR.

[26]  R. Gilbert,et al.  Patterns of p53 gene mutations in head and neck cancer: full-length gene sequencing and results of primary radiotherapy. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  M. Boyd,et al.  Regulation of p53 and MDM2 Activity by MTBP , 2005, Molecular and Cellular Biology.

[28]  R G Dale,et al.  The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. , 1985, The British journal of radiology.

[29]  J. Leal,et al.  Characterization of the p53 Response to Oncogene-Induced Senescence , 2008, PloS one.

[30]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[31]  G. Wahl,et al.  Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.

[32]  Goberdhan P Dimri,et al.  Methods to detect biomarkers of cellular senescence: the senescence-associated beta-galactosidase assay. , 2007, Methods in molecular biology.

[33]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[34]  L. Vassilev.  Small-Molecule Antagonists of p53-MDM2 Binding: Research Tools and Potential Therapeutics , 2004, Cell cycle.

[35]  A. Flahault,et al.  p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Richard D Riley,et al.  A Systematic Review of p53 as a Prognostic Factor of Survival in Squamous Cell Carcinoma of the Four Main Anatomical Subsites of the Head and Neck , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[37]  Zigang Dong,et al.  Post-translational modification of p53 in tumorigenesis , 2004, Nature Reviews Cancer.

[38]  A. Gudkov,et al.  The role of p53 in determining sensitivity to radiotherapy , 2003, Nature Reviews Cancer.

[39]  Manuel Serrano,et al.  Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin. , 2007, Cancer research.

[40]  R. Bargou,et al.  Selective Pharmacologic Activation of the p53-Dependent Pathway as a Therapeutic Strategy for Hematologic Malignancies , 2006, Cell cycle.

[41]  C. Reutelingsperger,et al.  Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. , 1998, Cytometry.

[42]  G. Evan,et al.  Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. , 2007, Cancer cell.

[43]  Guillermina Lozano,et al.  MDM2, an introduction. , 2003, Molecular cancer research : MCR.

[44]  G. Stark,et al.  p53-mediated growth suppression in response to Nutlin-3 in cyclin D1 transformed cells occurs independently of p21. , 2007, Cancer research.

[45]  M. Oren,et al.  Decision making by p53: life, death and cancer , 2003, Cell Death and Differentiation.

[46]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[47]  J. Manola,et al.  TP53 mutations and survival in squamous-cell carcinoma of the head and neck. , 2007, The New England journal of medicine.

[48]  S. O'Dea,et al.  5-Bromo-2-deoxyuridine activates DNA damage signalling responses and induces a senescence-like phenotype in p16-null lung cancer cells , 2007, Anti-cancer drugs.

[49]  T. Soussi.  p53 mutations and resistance to chemotherapy: A stab in the back for p73. , 2003, Cancer cell.

[50]  D. Meek.  Post-translational modification of p53. , 1994, Seminars in cancer biology.